Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Fundamental data now powered by FactSet with hourly updates!

ERAS | Erasca Inc

Index	RUT	P/E	-	EPS (ttm)	-1.79	Insider Own	38.70%	Shs Outstand	149.33M	Perf Week	-12.03%
Market Cap	320.20M	Forward P/E	-	EPS next Y	-1.13	Insider Trans	0.38%	Shs Float	92.60M	Perf Month	-19.08%
Income	-235.72M	PEG	-	EPS next Q	-0.24	Inst Own	41.54%	Short Float / Ratio	9.63% / 17.51	Perf Quarter	-17.83%
Sales	0.00M	P/S	-	EPS this Y	49.60%	Inst Trans	3.06%	Short Interest	8.92M	Perf Half Y	-24.01%
Book/sh	2.41	P/B	0.88	EPS next Y	-12.86%	ROA	-53.24%	Target Price	14.50	Perf Year	-72.03%
Cash/sh	2.10	P/C	1.01	EPS next 5Y	-	ROE	-62.21%	52W Range	2.11 - 9.25	Perf YTD	-50.81%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-56.57%	52W High	-77.08%	Beta	1.14
Dividend %	-	Quick Ratio	13.90	Sales past 5Y	0.00%	Gross Margin	-	52W Low	0.47%	ATR	0.14
Employees	129	Current Ratio	13.90	Sales Q/Q	-	Oper. Margin	0.00%	RSI (14)	26.54	Volatility	7.36% 5.06%
Optionable	Yes	Debt/Eq	0.16	EPS Q/Q	28.49%	Profit Margin	-	Rel Volume	0.87	Prev Close	2.12
Shortable	Yes	LT Debt/Eq	0.15	Earnings	Aug 10 AMC	Payout	-	Avg Volume	509.51K	Price	2.12
Recom	1.00	SMA20	-15.75%	SMA50	-17.46%	SMA200	-33.41%	Volume	445,714	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-30-23	Initiated	Mizuho	Buy	$9
Feb-24-23	Initiated	Goldman	Buy	$10
Feb-03-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$15

Sep-19-23 08:00AM	Erasca to Present at the Cantor Global Healthcare Conference (GlobeNewswire)
Sep-05-23 08:00AM	Erasca to Present at the Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
Aug-29-23 08:00AM	Erasca Doses First Patient in SEACRAFT-1 Phase 1b Trial Evaluating Naporafenib Plus Trametinib in Patients with RAS Q61X Solid Tumors (GlobeNewswire)
Aug-10-23 04:01PM	Erasca Reports Second Quarter 2023 Financial Results and Business Updates (GlobeNewswire)
Jul-12-23 06:35AM	Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation (Simply Wall St.)
04:01PM	Loading…
Jun-22-23 04:01PM	Erasca Granted FDA Orphan Drug Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 for the Treatment of Malignant Glioma (GlobeNewswire) -7.96%
Jun-15-23 06:22AM	Jonathan Lim Spends US$275k On Erasca Stock \ (Simply Wall St.)
Jun-06-23 10:53AM	Erasca Puts Certain Pipeline Programs On Chopping Block To Focus On Programs With Encouraging Activity Signals (Benzinga) -8.18%
Jun-05-23 04:01PM	Erasca Provides Update on Clinical Program for ERK Inhibitor ERAS-007 and Refines Pipeline (GlobeNewswire) +14.19%
Jun-01-23 08:00AM	Erasca to Present at Upcoming Investor Conferences (GlobeNewswire)
May-31-23 08:00AM	Erasca to Host Virtual Investor Event on Pipeline Updates with a Focus on ERAS-007 ERK Inhibitor (GlobeNewswire)
May-25-23 05:00PM	Erasca to Present Promising Preliminary HERKULES-3 Phase 1b Data at the 2023 ASCO Annual Meeting (GlobeNewswire)
09:01AM	With 42% stake, Erasca, Inc. (NASDAQ:ERAS) seems to have captured institutional investors' interest (Simply Wall St.)
May-16-23 08:00AM	Erasca Further Strengthens Business Leadership with Two Key Promotions (GlobeNewswire)
May-15-23 04:01PM	Erasca Reports First Quarter 2023 Financial Results and Business Updates (GlobeNewswire)
08:00AM	Loading…
May-02-23 08:00AM	Erasca to Present at the Bank of America Securities 2023 Health Care Conference (GlobeNewswire)
May-01-23 08:00AM	Erasca Granted FDA Fast Track Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 in Patients with Glioblastoma (GlobeNewswire)
Apr-26-23 05:00PM	Erasca Announces Two Poster Presentations at the 2023 ASCO Annual Meeting (GlobeNewswire)
Apr-25-23 08:00AM	Erasca Announces Publication of Promising Clinical Data Supporting the Therapeutic Potential of Naporafenib in Combination with Trametinib in NRAS-Mutant Melanoma (GlobeNewswire)
Apr-18-23 09:00AM	Erasca Presents Promising Initial Phase 1b Dose Escalation Data from FLAGSHP-1 for ERAS-601 Plus Cetuximab in Patients with Advanced Solid Tumors at the 2023 AACR Annual Meeting (GlobeNewswire)
Apr-12-23 07:07AM	Daily Vickers Top Buyers & Sellers for 04/12/2023 (Argus Research)
Apr-10-23 08:00AM	Erasca Strengthens Clinical and Regulatory Leadership with Two Key Appointments as Company Transitions to Late-Stage Development (GlobeNewswire) -8.83%
Mar-31-23 06:19AM	Trade Alert: The Co-Founder Of Erasca, Inc. (NASDAQ:ERAS), Jonathan Lim, Has Just Spent US$284k Buying A Few More Shares (Simply Wall St.)
Mar-30-23 04:21AM	6 analyst picks of the day: Walmart stock pops, Fluence upped to Buy \| Pro Recap (Investing.com)
Mar-23-23 04:01PM	Erasca Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Business Updates (GlobeNewswire)
Mar-14-23 04:31PM	Erasca Announces Poster Presentation at the 2023 AACR Annual Meeting (GlobeNewswire)
Feb-01-23 08:00AM	Erasca to Present at the Guggenheim Oncology Conference 2023 (GlobeNewswire)
Jan-16-23 06:19AM	We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth (Simply Wall St.)
Jan-11-23 03:04PM	11 Best All-Time Low Stocks To Buy Now (Insider Monkey) +8.00%
Jan-04-23 08:00AM	Erasca to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
08:00AM	Loading…
Dec-20-22 08:00AM	Erasca Announces First Patient Dosed in HERKULES-1 Phase 1b Trial Evaluating ERAS-007 and ERAS-601 MAPKlamp Combination in RAS/MAPK Pathway-Altered Solid Tumors (GlobeNewswire)
Dec-17-22 07:28AM	Co-Founder Jonathan Lim Just Bought A Handful Of Shares In Erasca, Inc. (NASDAQ:ERAS) (Simply Wall St.)
Dec-16-22 07:15AM	Erasca, Inc.'s (NASDAQ:ERAS) recent 16% pullback adds to one-year year losses, institutional owners may take drastic measures (Simply Wall St.)
Dec-13-22 08:00AM	Erasca Announces FDA Clearance of IND Application for CNS-Penetrant KRAS G12C Inhibitor ERAS-3490 in KRAS G12C-Mutated Advanced or Metastatic Solid Tumors (GlobeNewswire)
Dec-09-22 10:00AM	Erasca Oulicenses Its Mid-Stage Cancer Program To Novartis, Raises $100M Via Equity Offering (Benzinga) -22.30%
07:34AM	Erasca Announces Exclusive Worldwide License for Pan-RAF Inhibitor Naporafenib (GlobeNewswire)
07:32AM	Erasca Announces Pricing of Underwritten Offering of Common Stock (GlobeNewswire)
Nov-30-22 08:00AM	Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pierre Fabre to Evaluate ERAS-007 and Encorafenib Combination (GlobeNewswire) +6.34%
Nov-22-22 08:00AM	Erasca to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-14-22 09:55AM	Wall Street Analysts Predict a 126% Upside in Erasca, Inc. (ERAS): Here's What You Should Know (Zacks)
Nov-09-22 04:01PM	Erasca Reports Third Quarter 2022 Financial Results and Business Updates (GlobeNewswire)
Oct-20-22 08:00AM	Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Evaluate ERAS-007 and Palbociclib Combination (GlobeNewswire)
Oct-12-22 08:00AM	Erasca Announces Four Poster Presentations at the Upcoming 34th EORTC-NCI-AACR Symposium (GlobeNewswire)
Sep-26-22 08:00AM	Erasca to Present at the Bank of America Securities Precision Oncology Conference 2022 (GlobeNewswire)
Sep-09-22 08:31AM	Erasca to Present at the Morgan Stanley Global Healthcare Conference (GlobeNewswire)
Sep-08-22 11:08AM	Erasca Touts Promising Early Data From Lead Cancer Programs (Benzinga) -11.28%
Sep-07-22 04:05PM	Erasca Presents Promising Preliminary Phase 1/1b Monotherapy Data for ERAS-007 ERK and ERAS-601 SHP2 Inhibitors Supporting Ongoing and Future Combination Trials (GlobeNewswire) +6.21%
Aug-24-22 08:00AM	Erasca to Host R&D Day with KOL Dr. David Hong on Lead Clinical Programs ERAS-007 and ERAS-601 in Advanced Solid Tumors (GlobeNewswire)
Aug-23-22 09:55AM	Here's Why Erasca, Inc. (ERAS) Looks Ripe for Bottom Fishing (Zacks) +5.08%
08:00AM	Erasca and MD Anderson Announce Strategic Research and Development Collaboration in RAS/MAPK-Driven Cancers (GlobeNewswire)
Aug-19-22 09:55AM	Wall Street Analysts See an 111% Upside in Erasca, Inc. (ERAS): Can the Stock Really Move This High? (Zacks) -5.56%
Aug-11-22 04:05PM	Erasca Reports Second Quarter 2022 Financial Results and Business Updates (GlobeNewswire) -11.12%
Aug-08-22 09:29AM	Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation (Simply Wall St.)
Aug-03-22 09:55AM	Wall Street Analysts Believe Erasca, Inc. (ERAS) Could Rally 244%: Here's is How to Trade (Zacks)
Jul-27-22 06:00PM	Erasca, Inc. (ERAS) Gains But Lags Market: What You Should Know (Zacks)
Jul-21-22 06:00PM	Erasca, Inc. (ERAS) Stock Sinks As Market Gains: What You Should Know (Zacks)
Jul-18-22 06:15PM	Erasca, Inc. (ERAS) Gains As Market Dips: What You Should Know (Zacks)
09:55AM	Wall Street Analysts See a 288% Upside in Erasca, Inc. (ERAS): Can the Stock Really Move This High? (Zacks)
08:00AM	Erasca Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate ERAS-601 and Cetuximab Combination (GlobeNewswire)
Jul-12-22 06:00PM	Erasca, Inc. (ERAS) Stock Moves -0.32%: What You Should Know (Zacks)
Jul-06-22 06:15PM	Erasca, Inc. (ERAS) Outpaces Stock Market Gains: What You Should Know (Zacks)
Jun-09-22 09:55AM	Wall Street Analysts Believe Erasca, Inc. (ERAS) Could Rally 362%: Here's is How to Trade (Zacks)
Jun-03-22 09:00AM	Erasca to Present at the 2022 Jefferies Healthcare Conference (GlobeNewswire) +13.23%
Jun-02-22 08:00AM	Erasca Announces Trial to Evaluate ERAS-007 in Combination with KRAS G12C Inhibitor in KRAS-Driven Cancers (GlobeNewswire)
May-25-22 08:00AM	Erasca Strengthens Clinical and Commercial Leadership with Three Key Appointments (GlobeNewswire)
May-23-22 09:55AM	Erasca, Inc. (ERAS) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
May-12-22 04:01PM	Erasca Reports First Quarter 2022 Financial Results and Business Updates (GlobeNewswire)
May-03-22 08:00AM	Erasca to Present at the Bank of America Securities 2022 Healthcare Conference (GlobeNewswire)
Apr-27-22 08:00AM	Erasca Appoints Jean Liu to its Board of Directors (GlobeNewswire)
Apr-15-22 07:42AM	Insiders at Erasca, Inc. (NASDAQ:ERAS) recouped some losses this week after buying this year, still down US$111k (Simply Wall St.)
Apr-12-22 04:01PM	Erasca Presents Compelling Preclinical Data Supporting Clinical Development of Potentially Best-In-Class Programs ERAS-007, ERAS-601, and ERAS-3490 at 2022 AACR Annual Meeting (GlobeNewswire)
Apr-06-22 08:00AM	Erasca To Host Investor Event with Leading KOL Dr. Scott Kopetz on Therapeutic Opportunities in Cancers Driven by the RAS/MAPK Pathway (GlobeNewswire)
Mar-24-22 04:05PM	Erasca Reports Fourth Quarter 2021 Financial Results and Business Updates (GlobeNewswire)
Mar-10-22 08:00AM	Erasca Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate ERAS-007 and Cetuximab Combination (GlobeNewswire)
Mar-08-22 04:31PM	Erasca Announces Six Poster Presentations at the 2022 AACR Annual Meeting (GlobeNewswire)
Mar-01-22 04:14PM	SLR Investment Corp. Announces Quarter and Fiscal Year Ended December 31, 2021 Financial Results; (GlobeNewswire)
Feb-08-22 09:04AM	Is a Surprise Coming for Erasca (ERAS) This Earnings Season? (Zacks)
Feb-03-22 08:00AM	Erasca to Present at the Guggenheim Healthcare Talks 2022 Oncology Day (GlobeNewswire)
Jan-27-22 01:38PM	Edmonds Duncan Registered Investment Advisors, LLC Buys VanEck Vectors Semiconductor ETF, ... (GuruFocus.com)
Jan-18-22 08:00AM	Erasca Strengthens Leadership Team with Two Key Executive Appointments (GlobeNewswire) -5.95%
Jan-04-22 08:00AM	Erasca to Present at the 40th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-24-21 12:38AM	Orbimed Advisors Llc Buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, ... (GuruFocus.com)
Dec-18-21 12:38AM	Orbimed Advisors Llc Buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, ... (GuruFocus.com)
Dec-17-21 08:00AM	Erasca Announces FDA Clearance of IND Application for ERAS-801 in Glioblastoma Multiforme and Collaboration with GCAR for Potential Inclusion in GBM AGILE Clinical Trial (GlobeNewswire)
Dec-16-21 09:38AM	VIP Health Care Portfolio Buys Thermo Fisher Scientific Inc, Royalty Pharma PLC, Charles River ... (GuruFocus.com)
Dec-15-21 05:46AM	How Much Of Erasca, Inc. (NASDAQ:ERAS) Do Insiders Own? (Simply Wall St.)
Dec-14-21 08:00AM	Erasca Added to the Nasdaq Biotechnology Index (GlobeNewswire)
Dec-11-21 05:38AM	Penn Series Small Cap Index Fund Buys AMC Entertainment Holdings Inc, DigitalOcean Holdings ... (GuruFocus.com)
Nov-16-21 08:00AM	Erasca to Present at the Evercore ISI 4th Annual HealthCONx Conference (GlobeNewswire)
Nov-10-21 04:05PM	Erasca Reports Third Quarter 2021 Financial Results and Business Updates (GlobeNewswire)
Oct-25-21 04:01PM	Erasca Announces Presentation of Preclinical Data on ERAS-801, a CNS-Penetrant EGFR Inhibitor with Broad Activity against Oncogenic EGFR Alterations, at AACR Conference on Brain Cancer (GlobeNewswire)
Oct-16-21 09:45AM	Quite a few insiders invested in Erasca, Inc. (NASDAQ:ERAS) last year which is positive news for shareholders (Simply Wall St.)

Erasca, Inc. is a clinical stage precision oncology company, It focuses on discovering, developing, and commercializing therapies for RAS/MAPK pathway-driven cancers. It has assembled a wholly owned or controlled RAS/MAPK pathway focused pipeline comprising modality-agnostic programs. The company was founded by Jonathan E. Lim on July 2, 2018 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lim Jonathan E	Chairman & CEO	Jun 08	Buy	2.75	100,000	275,000	18,396,216	Jun 08 08:54 PM
Casdin Alexander W.	Director	Apr 10	Buy	2.76	20,000	55,230	463,974	Apr 11 08:23 AM
Lim Jonathan E	Chairman & CEO	Mar 28	Buy	2.84	100,000	284,000	18,296,216	Mar 28 09:24 PM
Lim Jonathan E	Chairman & CEO	Jan 10	Buy	3.86	60,000	231,420	20,256,222	Jan 10 04:46 PM
Bristol James Arthur	Director	Dec 21	Buy	4.14	20,000	82,800	20,000	Dec 22 09:26 PM
Start Valerie Denise Harding	Director	Dec 21	Buy	4.64	10,000	46,400	10,000	Dec 22 09:28 PM
Casdin Alexander W.	Director	Dec 15	Buy	4.87	20,000	97,490	443,974	Dec 15 04:47 PM
Lim Jonathan E	Chairman & CEO	Dec 14	Buy	4.99	40,000	199,600	20,196,222	Dec 15 11:53 AM
Chen Bihua	Director	Dec 13	Buy	6.50	307,692	1,999,998	10,813,246	Dec 20 05:42 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ERAS | Erasca Inc

Upgrade your FINVIZ experience